Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation
E-Mail IMAGE: Charu Aggarwal, MD, MPH (top), Ronac Mamtani, MD, (bottom left), and Lova Sun, MD. view more Credit: Penn Medicine PHILADELPHIA--Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center at the University of Pennsylvania. In a new study published online today in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated wi...
Source: eurekalert.org